What drove Quest Diagnostics' revenue and earnings growth in 2000?

The main driver was the August 1999 acquisition of SmithKline Beecham's clinical lab business, which lifted revenue by about $1.2 billion. Improved average revenue per requisition, higher requisition volume, and early integration synergies also contributed. Net income moved from a $3.4 million loss to $102.1 million, though the year-over-year comparison is distorted by 1999 special charges and the partial year of SBCL ownership.

How strong is the company's balance sheet and debt position?

Stronger than a year earlier. Long-term debt fell to $760.7 million from $1.17 billion, and stockholders' equity rose to $1.03 billion from $862 million. Cash reached $171.5 million. Still, the company carries about $265 million of short-term borrowings (mostly the receivables facility), and its credit agreement restricts dividends, so no dividend is expected.

What are the main risks to the investment case?

The key risks are integration execution (service disruptions could push customers to competitors, and integration may not finish until 2003), billing and collection problems (bad debt at 7% of revenue), pending private class actions and qui tam suits tied largely to SBCL's pre-acquisition billing, and possible Medicare fee cuts or coinsurance changes. Management has indemnification from Corning and SmithKline Beecham for much of the pre-acquisition exposure, but indemnities are limited in scope and amount.

What do management's growth targets look like?

Management expects earnings growth before special charges of more than 30% annually over the next several years, supported by about $150 million in SBCL synergies. The company also points to demand drivers including an aging population, genomic and esoteric testing, clinical trials, direct-to-consumer testing, and anatomic pathology. These statements are forward-looking and carry the cautionary risks listed in the filing.

Will the stock split affect the per-share numbers in this filing?

Yes, the company approved a two-for-one stock split on February 21, 2001, to be effected by a stock dividend on May 31, 2001, for holders of record on May 16, 2001, subject to stockholder approval of increasing authorized shares from 100 million to 300 million. The per-share figures in this 10-K are not restated for the split, so reported EPS will roughly halve on a post-split basis.

DGX 10-K FY2000 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed April 2, 2001. Cited figures are marked; the original filing is the authoritative source.

Quest Diagnostics (DGX) reported FY2000 net revenues of $3.42 billion^a, up from $2.21 billion in 1999, driven mainly by the August 1999 acquisition of SmithKline Beecham Clinical Laboratories (SBCL).

Net income swung to $102.1 million^b ($2.16 diluted EPS) from a $3.4 million loss in 1999. Excluding special items and extraordinary losses, income rose to $106.2 million from $41.2 million. Adjusted EBITDA reached $459.4 million, or 13.4% of net revenues, versus $237.0 million (11.2%) a year earlier.

Operating cash flow was $369.5 million^c, and the company prepaid $155 million of bank term loans during the fourth quarter. The balance sheet is considerably healthier. Long-term debt fell to $760.7 million from $1,171.4 million, supported by a $256 million receivables-backed financing completed in July 2000, and common equity rose to $1.03 billion.

Management points to roughly $150 million^d in targeted annual SBCL synergies (about $50 million achieved in 2000 and an additional $50 to $70 million expected in 2001), and it projects earnings growth above 30% annually before special charges. Integration is about 85% complete, with principal laboratory consolidation expected in early Q2 2001 and the full process possibly running to 2003. Key risks remain.

Bad debt expense rose to 7.0% of revenue, and the company faces pending private billing claims and class actions tied to SBCL, with reserves of about $88 million. Medicare reimbursement is also a live concern: the Medicare share of revenue has declined from 20% in 1995 to 13% in 2000, and proposals on coinsurance, competitive bidding, and carrier consolidation could pressure fees. Investors should also note that the 2-for-1 stock split approved in February 2001 has not yet been reflected in per-share figures.

02—Key points

Key Highlights

Net revenues of $3.42 billion in 2000, up 55% year over year, largely reflecting the SBCL acquisition; the company describes itself as the nation's largest clinical laboratory.
Net income of $102.1 million ($2.16 diluted EPS) versus a $3.4 million loss in 1999; income before extraordinary loss and special items reached $106.2 million.
Adjusted EBITDA of $459.4 million (13.4% margin), up from $237.0 million (11.2%) in 1999, with margin expansion attributed to operating improvements and SBCL synergies.
Long-term debt cut to $760.7 million from $1.17 billion, with $155 million of term loans prepaid in Q4 2000 and a $256 million receivables financing used to pay down the credit facility.
SBCL integration roughly 85% complete; approximately $150 million in annual synergies targeted, with about $50 million achieved in 2000 and $50 to $70 million expected in 2001.
Bad debt expense rose to 7.0% of net revenues (from 6.7%), a key watch item as SBCL collection practices are brought up to Quest standards.
Medicare share of revenue fell to 13% from 20% in 1995, but pending federal reimbursement changes, competitive bidding proposals, and ongoing billing-related litigation (about $88 million in reserves) remain material risks.

03—Questions

Frequently Asked Questions

What drove Quest Diagnostics' revenue and earnings growth in 2000?
The main driver was the August 1999 acquisition of SmithKline Beecham's clinical lab business, which lifted revenue by about $1.2 billion. Improved average revenue per requisition, higher requisition volume, and early integration synergies also contributed. Net income moved from a $3.4 million loss to $102.1 million, though the year-over-year comparison is distorted by 1999 special charges and the partial year of SBCL ownership.
How strong is the company's balance sheet and debt position?
Stronger than a year earlier. Long-term debt fell to $760.7 million from $1.17 billion, and stockholders' equity rose to $1.03 billion from $862 million. Cash reached $171.5 million. Still, the company carries about $265 million of short-term borrowings (mostly the receivables facility), and its credit agreement restricts dividends, so no dividend is expected.
What are the main risks to the investment case?
The key risks are integration execution (service disruptions could push customers to competitors, and integration may not finish until 2003), billing and collection problems (bad debt at 7% of revenue), pending private class actions and qui tam suits tied largely to SBCL's pre-acquisition billing, and possible Medicare fee cuts or coinsurance changes. Management has indemnification from Corning and SmithKline Beecham for much of the pre-acquisition exposure, but indemnities are limited in scope and amount.
What do management's growth targets look like?
Management expects earnings growth before special charges of more than 30% annually over the next several years, supported by about $150 million in SBCL synergies. The company also points to demand drivers including an aging population, genomic and esoteric testing, clinical trials, direct-to-consumer testing, and anatomic pathology. These statements are forward-looking and carry the cautionary risks listed in the filing.
Will the stock split affect the per-share numbers in this filing?
Yes, the company approved a two-for-one stock split on February 21, 2001, to be effected by a stock dividend on May 31, 2001, for holders of record on May 16, 2001, subject to stockholder approval of increasing authorized shares from 100 million to 300 million. The per-share figures in this 10-K are not restated for the split, so reported EPS will roughly halve on a post-split basis.

04—Continue

← View all 10-K filings